Stem cell mobilization · 11 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
EAR and G-CSF Variant #01 | — | R 41 054 | — | — | — | — | — | — |
IGEV and G-CSF Variant #01 | — | R 17 637 | — | — | — | — | — | — |
Cytarabine and G-CSF Variant #01 | — | R 11 717 | — | — | — | — | — | — |
Cytarabine, Ifosfamide, G-CSF Variant #01 | — | R 11 450 | — | — | — | — | — | — |
Cytarabine and Etoposide (CYVE) and G-CSF Variant #01 | — | R 8 832 | — | — | — | — | — | — |
DexaBEAM and G-CSF Variant #01 Partial | — | R 2 200 | — | — | — | — | — | — |
DCEP and G-CSF Variant #01 | — | R 1 486 | — | — | — | — | — | — |
CAD and G-CSF Variant #01 | — | R 1 160 | — | — | — | — | — | — |
Cyclophosphamide and G-CSF Variant not yet assigned - class-based regimen | — | R 357 | — | — | — | — | — | — |
Plerixafor and G-CSF Variant #01 Partial | — | — | — | — | — | — | — | — |
Motixafortide and G-CSF Variant #01 Partial | — | — | — | — | — | — | — | — |
11 of 11 regimens shown